Mass Balance Study of [14C]RAY1216 in Healthy Adult Male Subjects in China

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 18, 2023

Primary Completion Date

November 1, 2023

Study Completion Date

November 15, 2023

Conditions

Pharmacokinetics

Interventions

DRUG

[14C] RAY1216

400 mg suspension containing 100μCi of \[14C\]RAY1216

Trial Locations (1)

The First Affiliated Hospital of Bengbu Medical College, Bengbu

All Listed Sponsors

lead

Guangdong Raynovent Biotech Co., Ltd

INDUSTRY

NCT06362460 - Mass Balance Study of [14C]RAY1216 in Healthy Adult Male Subjects in China | Biotech Hunter | Biotech Hunter